Systemic administration of EPO is used to treat adult anemia and has been discussed as a potential treatment for atrophic AMD due to its neuroprotective effects on the retina [7,37]; however, there are associations between increased serum EPO and severity of CNV in AMD patients [9]. This evidence concerns the gene EPO and anemia (phenotype).